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Abstract: Several diseases cause cystic or cyst-like parenchymal lung abnormalities including adult pulmonary Langerhan’s 
cell histiocytosis (PLCH), lymphangioleiomyomatosis (LAM), emphysema, end-stage interstitial lung disease, and cystic 
bronchiectasis. Many of these diseases can now be diagnosed with high accuracy by the use of high-resolution computerized 
tomography (HRCT). In fact, HRCT of chest has proved a major breakthrough in the diagnosis of these diseases. We are 
presenting a young man with a cystic lung disease in which, the HRCT findings were virtually diagnostic of that disease. The 
clinical and HRCT findings of this disease along with its differential diagnosis are discussed in this paper. 
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Case history 
A 24 year old, Indian man was referred to chest clinic 
because of worsening cough and exertional breathlessness 
despite a six-month treatment with anti-tuberculous 
medications. Six months prior to this referral, he was 
admitted to hospital for investigation of cough and 
exertional breathlessness of six months duration. At that 
time, he was found to have miliary shadows on chest 
radiograph (Figure 1). During that admission, extensive 
work-up failed to prove miliary tuberculosis. Three 
samples of sputum for Acid-fast bacilli (AFB) smear and 
culture were negative, tuberculin test was negative, and 
transbronchial lung biopsy revealed unremarkable lung 
parenchyma, with no granuloma or malignancy detected in 
the biopsy specimen. Bronchoalveolar lavage for AFB 
smear and culture was also negative and cytology showed 
80% macrophages, 12% neutrophils, lymphocytes 5%, 
and eosinophils 3%. Due to the high prevalence of 
tuberculosis in Qatar, empirical treatment for miliary 
tuberculosis was started and he was discharged home to 
be followed up in tuberculosis clinic. 
 
Despite six months of anti-tuberculous medications, his 
symptoms persisted. He continued to have dry cough and 
breathlessness on mild exertion. He had no history of 
hemoptysis, fever, skin rash or joint pain.  
 
He was a heavy smoker; he smoked 20 cigarettes per 
day for 10 years prior to his presentation and worked as a 
mechanic. He never kept birds or pets at home and did 
not travel during the previous year. 
 
Physical examination done in chest clinic revealed a 
young man with frequent coughing but not tachypneic or 
cyanosed, and there were no signs of pulmonary 
hypertension or clubbing. His chest examination revealed 
normal breath sounds bilaterally with no crackles or 
ronchi. 
 
Oxygen saturation by pulse oxymeter was 96%. His 
blood count, blood urea nitrogen and serum electrolytes 
were normal. Pulmonary function testing revealed FEV1 
76% of predicted, FVC 73% of predicted, and FEV1/FVC 
87%, with DLCO 70% of predicted. High resolution 
computerized scan (HRCT) of chest was done (Figure 2). 
 
 
 
 
 
 
Figure 1  Chest radiograph of the patient showing diffuse reticular 
and tiny miliary shadows 
 
 
Figure 2  HRCT of the chest showing variable-sized cysts, with 
irregular, thin, and thick walls distributed predominantly in the 
upper lobes (arrows). Micronodular infiltrates are also seen. 
 
Questions 
Question 1: What are the findings on HRCT of the chest? 
And what is the diagnosis? 
Question 2: Is lung biopsy mandatory for diagnosis in this 
patient? 
Question 3: If lung biopsy is done, which stain is usually 
used? 
Question 4: What will you advise this patient? 
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Answers
Answer to question 1: The HRCT of the chest shows 
multiple thin and thick wall cystic changes that are 
predominant in the upper lobes along with micronodular 
opacities that are diffusely scattered all over the lungs. 
Being a young smoker with the predominant involvement 
of the upper lobes by the cystic changes and the presence 
of associated micronodular infiltrates, are almost 
diagnostic of adult pulmonary Langerhan’s histiocytosis. 
Answer to question 2: The HRCT appearance is almost 
diagnostic. Although lung biopsy may be used to confirm 
the radiological diagnosis, it is not mandatory with such 
typical clinical and radiological presentation. 
 
Answer to question 3: Immunohistochemical staining 
with monoclonal antibodies directed against the 
membrane antigen CD1a is used to stain the Langerhan’s 
cells. Positive staining for intracellular S100 protein, 
although widely used in the past to identify Langerhan’s 
cells, is not specific to these cells and can also be 
observed in other cell type. 
 
Answer to question 4: Smoking cessation is mandatory 
due to the strong association between PLCH and smoking 
that suggests a causal role of smoking in this disease. 
 
Discussion
Pulmonary Langerhan’s cell histiocytosis (PLCH) in 
adults is a rare disorder of unknown etiology that occurs 
almost exclusively in smokers [1]. There is usually a 
considerable time delay before the diagnosis is made. The 
average interval between the onset of clinical symptoms 
and diagnosis is about six months [2]. 
 
The etiology of PLCH remains obscure, but the strong 
association (90-100%) with cigarette smoking suggests a 
role for tobacco smoke in the pathogenesis of this disease. 
The details regarding how tobacco smoke triggers the 
formation of PLCH lesions remains imprecise. An immune 
response to a component of tobacco smoke has been 
suggested [1]. Although PLCH occurs predominantly in 
smokers, it is unclear why only a small percentage of 
smokers have this problem, suggesting that other 
unknown factors are in play. Furthermore, the 
development of PLCH following Hodgkin’s disease or its 
treatment has also been reported previously. This may 
raise the question of common etiologic factors between 
smoking and Hodgkin’s disease or immunosuppression [3]. 
 
PLCH predominantly affects young adults, with a 
frequency peak at 20-40 years of age. Accurate 
epidemiological data for PLCH are not available and the 
exact incidence of the disease is unknown [1]. Although 
there does not appear to be gender predominance, female 
patients with PLCH tend to present later in life. 
 
The most common symptoms are dry cough and 
exertional breathlessness. Pneumothorax may develop in 
about 10-20% of cases. Hemoptysis is uncommon and 
should not be attributed to PLCH until other causes 
(particularly lung cancer in these smoking patients) have 
been ruled out [1,2,4,5]. 
 
HRCT of the chest has revolutionized the diagnostic 
approach of PLCH. The CT scan findings of typical cystic 
changes that predominantly affect the upper lobes, along 
with micronodular infiltration in an adult smoker are 
virtually diagnostic of this disorder [6,7,8]. Many reports 
have confirmed the high diagnostic reliability of HRCT in 
PLCH[6,7,8]. Less inter-observer variability has been 
reported with radiographic diagnosis of PLCH as compared 
to other lung diseases [7]. 
 
Table 1 describes the distinguishing clinical and CT scan 
appearance of the major cystic lung diseases. Open lung 
biopsy may not be required when the CT scan appearance 
is typical for PLCH, particularly in young adults with a 
history of heavy smoking. Lung biopsy may be needed in 
selected cases when the CT scan shows isolated 
micronodular changes [6]. 
 
The lung pathology typically reveals the presence of 
Langerhan’s cells, which can be confirmed by 
immunohistochemical staining with monoclonal antibodies 
directed against the membrane antigen CD1a. Positive 
staining for the intracellular S100 protein, although widely 
used to identify Langerhan’s cells, is not specific to these 
cells and can be observed in neuroendocrine cells and 
some macrophages [1]. 
 
Pulmonary function testing (PFT) is abnormal in the 
majority of patients with PLCH. DLCO is reduced in more 
than 75% of patients. Pure restrictive, obstructive, or 
mixed pattern can be observed [9]. 
 
The course of adult PLCH is variable and unpredictable, 
ranging from a symptomatic course to progressive disease 
that leads to respiratory failure and death over periods of 
months [9]. 
 
Although smoking cessation is considered a mandatory 
step in the treatment of patients with this disorder, 
nevertheless, no randomized double-blind studies have 
been published regarding treatment of this disorder. The 
long-term effectiveness of smoking cessation on the 
natural history of PLCH remains controversial, and only 
few case reports documenting partial or complete 
improvement of the disease following smoking cessation 
have been published in literature [10,11,12]. 
 
Glucocorticoid therapy attenuates the constitutional 
symptoms and is advocated on empirical grounds in the 
treatment of recent-onset symptomatic nodular PLCH. It 
should be highlighted, however, that there are no 
evidence-based data for the use of this treatment in PLCH 
[1]. 
 
Our patient had a significant clinical and radiological 
improvement that occurred in temporal association with 
smoking cessation, which may add evidence to the 
effectiveness of smoking cessation as a treatment 
modality for PLCH. However, the long-term efficacy of this 
type of therapy needs to be elucidated in future. PLCH 
should be a diagnostic consideration in young smoking 
patient with cystic lung disease. 
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Table 1  Characteristic CT appearance of major cystic lung diseases 
  
PLCH 
(Figure 2) 
Lymphangioleimyomatosis 
(Figure 3) 
Cenrtilobular emphysema 
(Figure 4) 
Bronchiectasis 
(Figure 5) 
Cyst size  Variable Variable 
Variable with centrilobular 
arteriole in the center of the 
cyst 
Variable 
Cyst wall 
thickness 
Both thick and thin  Thin  Invisible 
Thick with signet ring 
appearance 
Cyst shape 
 Variable, irregular, 
confluence of adjacent 
cysts 
Usually rounded  Polygonal, may be variable  Variable 
Cyst distribution 
Predominantly upper 
lobes, sparing of 
costophrenic angles 
Diffusely and uniformly distributed 
all over the lungs 
Mainly upper but can be 
anywhere 
Variable 
Micronodules  Present  Usually absent  Absent  Usually absent 
Clinically 
Almost always in 
smokers (usually young) 
Almost all are females of 
childbearing age 
Usually smokers  Sputum production 
 
Figure 3  HRCT in a woman with lymphangioleiomyomatosis 
showing diffuse, rounded, and thin walled cysts. 
 
 
Figure 4  HRCT in a patient with emphysema showing multiple 
polygonal translucencies, with almost invisible walls. 
 
 
 Figure 5  HRCT in a patient with cystic bronchiectasis showing 
dilatation of the bronchioles with thickening of their walls. Signet 
ring appearance is seen (arrow) 
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